[go: up one dir, main page]

WO2003000842A3 - Novel proteins and nucleic acids encoding same - Google Patents

Novel proteins and nucleic acids encoding same Download PDF

Info

Publication number
WO2003000842A3
WO2003000842A3 PCT/US2002/017443 US0217443W WO03000842A3 WO 2003000842 A3 WO2003000842 A3 WO 2003000842A3 US 0217443 W US0217443 W US 0217443W WO 03000842 A3 WO03000842 A3 WO 03000842A3
Authority
WO
WIPO (PCT)
Prior art keywords
small molecule
molecule target
nucleic acids
acids encoding
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/017443
Other languages
French (fr)
Other versions
WO2003000842A2 (en
Inventor
Michele L Agee
David W Anderson
Constance Berghs
Stacie J Casman
Elina Catterton
Vincent A Dipippo
Shlomit R Edinger
Andrew Eisen
Karen Ellerman
Esha A Gangolli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CuraGen Corp filed Critical CuraGen Corp
Priority to CA002447941A priority Critical patent/CA2447941A1/en
Priority to JP2003507229A priority patent/JP2005518185A/en
Priority to EP02765778A priority patent/EP1578905A2/en
Publication of WO2003000842A2 publication Critical patent/WO2003000842A2/en
Anticipated expiration legal-status Critical
Publication of WO2003000842A3 publication Critical patent/WO2003000842A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides novel isolated polynucleotides and small molecule target polypeptides encoded by the polynucleotides. Antibodies that immunospecifically bind to a novel small molecule target polypeptide or any derivative, variant, mutant or fragment of that polypeptide, polynucleotide or antibody are disclosed, as are methods in which the small molecule target polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states. More specifically, the present invention discloses methods of using recombinantly expressed and/or endogenously expressed proteins in various screening procedures for the purpose of identifying therapeutic antibodies and therapeutic small molecules associated with diseases.
PCT/US2002/017443 2001-06-04 2002-06-04 Novel proteins and nucleic acids encoding same Ceased WO2003000842A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002447941A CA2447941A1 (en) 2001-06-04 2002-06-04 Novel proteins and nucleic acids encoding same
JP2003507229A JP2005518185A (en) 2001-06-04 2002-06-04 Novel protein and nucleic acid encoding it
EP02765778A EP1578905A2 (en) 2001-06-04 2002-06-04 Novel proteins and nucleic acids encoding same

Applications Claiming Priority (72)

Application Number Priority Date Filing Date Title
US29560701P 2001-06-04 2001-06-04
US29566101P 2001-06-04 2001-06-04
US60/295,661 2001-06-04
US60/295,607 2001-06-04
US60/295,573 2001-06-05
US29641801P 2001-06-06 2001-06-06
US29640401P 2001-06-06 2001-06-06
US60/296,404 2001-06-06
US60/296,418 2001-06-06
US29657501P 2001-06-07 2001-06-07
US60/296,575 2001-06-07
US29741401P 2001-06-11 2001-06-11
US60/297,414 2001-06-11
US29757301P 2001-06-12 2001-06-12
US29756701P 2001-06-12 2001-06-12
US60/297,567 2001-06-12
US29828501P 2001-06-14 2001-06-14
US60/298,285 2001-06-14
US29852801P 2001-06-15 2001-06-15
US60/298,528 2001-06-15
US29913301P 2001-06-18 2001-06-18
US60/299,133 2001-06-18
US29923001P 2001-06-19 2001-06-19
US60/299,230 2001-06-19
US29994901P 2001-06-21 2001-06-21
US60/299,949 2001-06-21
US30017701P 2001-06-22 2001-06-22
US60/300,177 2001-06-22
US30088301P 2001-06-26 2001-06-26
US60/300,883 2001-06-26
US30153001P 2001-06-28 2001-06-28
US30155001P 2001-06-28 2001-06-28
US60/301,550 2001-06-28
US60/301,530 2001-06-28
US30295101P 2001-07-03 2001-07-03
US60/302,951 2001-07-03
US30889001P 2001-07-31 2001-07-31
US60/308,890 2001-07-31
US32229701P 2001-09-14 2001-09-14
US60/322,297 2001-09-14
US32466901P 2001-09-25 2001-09-25
US60/324,669 2001-09-25
US33747701P 2001-12-03 2001-12-03
US60/337,477 2001-12-03
US34156201P 2001-12-14 2001-12-14
US60/341,562 2001-12-14
US35865602P 2002-02-21 2002-02-21
US35912202P 2002-02-21 2002-02-21
US60/358,656 2002-02-21
US60/359,122 2002-02-21
US35903502P 2002-02-22 2002-02-22
US35912102P 2002-02-22 2002-02-22
US35903402P 2002-02-22 2002-02-22
US35897802P 2002-02-22 2002-02-22
US60/359,121 2002-02-22
US60/358,978 2002-02-22
US60/359,034 2002-02-22
US60/359,035 2002-02-22
US35996402P 2002-02-27 2002-02-27
US60/359,964 2002-02-27
US36085802P 2002-03-01 2002-03-01
US60/360,858 2002-03-01
US36367602P 2002-03-12 2002-03-12
US36343002P 2002-03-12 2002-03-12
US60/363,676 2002-03-12
US60/363,430 2002-03-12
US37134602P 2002-04-10 2002-04-10
US60/371,346 2002-04-10
US37944402P 2002-05-10 2002-05-10
US60/379,444 2002-05-10
US16061902A 2002-06-03 2002-06-03
US10/160,619 2002-06-03

Publications (2)

Publication Number Publication Date
WO2003000842A2 WO2003000842A2 (en) 2003-01-03
WO2003000842A3 true WO2003000842A3 (en) 2005-11-03

Family

ID=34744079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/017443 Ceased WO2003000842A2 (en) 2001-06-04 2002-06-04 Novel proteins and nucleic acids encoding same

Country Status (2)

Country Link
JP (1) JP2005518185A (en)
WO (1) WO2003000842A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056138B2 (en) 2002-03-01 2015-06-16 Bracco Suisse Sa Multivalent constructs for therapeutic and diagnostic applications
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041494B2 (en) 2000-11-15 2006-05-09 Icagen, Inc. DNA encoding Slo2 and Slo4, potassium channel
US6815181B2 (en) * 2001-07-09 2004-11-09 Applera Corporation Nucleic acid molecules encoding human secreted hemopexin-related proteins
ES2692166T3 (en) * 2003-03-03 2018-11-30 Dyax Corp. Peptides that specifically bind to the HGF receptor (cMet) and uses thereof
PL1725249T3 (en) 2003-11-06 2014-06-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JP5234734B2 (en) 2004-06-01 2013-07-10 ジェネンテック， インコーポレイテッド Antibody-drug conjugates and methods
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JP2006217859A (en) * 2005-02-10 2006-08-24 Japan Health Science Foundation Method for screening therapeutic or preventive agent for Alzheimer's disease, method for diagnosing Alzheimer's disease, and method for predicting the risk of developing Alzheimer's disease
EP1849877A1 (en) * 2006-04-24 2007-10-31 Erasmus University Medical Center Rotterdam Replicative history of T-and B-cell subsets
DE102007017433A1 (en) * 2007-04-03 2008-10-09 Eberhard-Karls-Universität Tübingen Universitätsklinikum Identifying substances suitable for treating a glucose metabolism disorder comprises determining if a test substance inhibits the activity or expression of FYVE finger-containing phosphatidylinositol kinase
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
MA34277B1 (en) 2010-04-15 2013-06-01 Spirogen Developments Sarl PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
CN119552249A (en) 2010-06-08 2025-03-04 基因泰克公司 Cysteine engineered antibodies and conjugates
CN103313990B (en) 2010-11-17 2016-07-20 基因泰克公司 Alanyl maytansinol antibody coupling matter
WO2012112955A2 (en) 2011-02-17 2012-08-23 The Trustees Of Columbia University In The City Of New York Methods for identifying subjects with a genetic risk for developing iga nephropathy
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
JP5864918B2 (en) * 2011-07-06 2016-02-17 国立大学法人東北大学 Autotaxin isoform-specific antibody and detection method
US11135303B2 (en) 2011-10-14 2021-10-05 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
DK2766048T3 (en) 2012-10-12 2015-03-02 Spirogen Sarl PYRROLOBENZODIAZEPINS AND CONJUGATES THEREOF
NZ707543A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
BR112015008173A2 (en) 2012-10-12 2017-11-28 Adc Therapeutics Sarl pyrrolobenzodiazepine-anti-psma antibody conjugates
RS56520B1 (en) 2012-10-12 2018-02-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
LT2906298T (en) 2012-10-12 2018-12-27 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
BR112015023070B1 (en) 2013-03-13 2022-06-07 Genentech, Inc. Pyrrolobenzodiazepine conjugates and compounds, pharmaceutical composition comprising the same, as well as their uses for the treatment of a proliferative disease
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
KR102066318B1 (en) 2013-03-13 2020-01-14 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
US10202647B2 (en) 2013-04-12 2019-02-12 The Trustees Of Columbia University In The City Of New York Mutations in DSTYK cause dominant urinary tract malformations
EP3033111B1 (en) 2013-08-12 2019-03-13 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
UA118113C2 (en) 2013-12-16 2018-11-26 Дженентек, Інк. Peptidomimetic compounds and antibody-drug conjugates thereof
CA2928952A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
CN105828840B (en) 2013-12-16 2020-08-04 基因泰克公司 1- (chloromethyl) -2, 3-dihydro-1H-benzo [ e ] indole dimer antibody-drug conjugate compounds and methods of use and treatment
JP6531166B2 (en) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugate
WO2016040856A2 (en) 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP6622293B2 (en) 2014-09-12 2019-12-18 ジェネンテック， インコーポレイテッド Anthracycline disulfide intermediates, antibody-drug conjugates, and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA2959689A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
WO2016072936A1 (en) * 2014-11-03 2016-05-12 Nanyang Technological University Novel recombinant expression systems
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3433621A1 (en) 2016-03-25 2019-01-30 H. Hoffnabb-La Roche Ag Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN109152843A (en) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 PROTAC antibody conjugates and methods of using the same
JP7022080B2 (en) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR102181375B1 (en) 2017-02-08 2020-11-25 에이디씨 테라퓨틱스 에스에이 Pyrrolobenzodiazepine-antibody conjugate
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
HUE059828T2 (en) 2017-04-18 2023-01-28 Medimmune Ltd Pyrrolobenzodiazepine conjugates
BR112019021880A2 (en) 2017-04-20 2020-06-02 Adc Therapeutics Sa COMBINATION THERAPY WITH ANTI-AXL-DRUG ANTIBODY CONJUGATE
MX2019015042A (en) 2017-06-14 2020-08-06 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc.
RS62928B1 (en) 2017-08-18 2022-03-31 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US10301319B2 (en) 2017-09-20 2019-05-28 Ph Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CN113056287A (en) 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 Conjugated chemical degradation inducers and methods of use
CN113227119A (en) 2018-12-10 2021-08-06 基因泰克公司 Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
BR112021018260A2 (en) 2019-03-15 2021-11-23 Medimmune Ltd Azetidobenzodiazepine dimers and conjugates comprising the same for use in the treatment of cancer
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
AU2021362997A1 (en) 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
AU2024257248A1 (en) 2023-04-17 2025-11-06 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS. ACTA 1519, vol. 1-2, 2001, pages 117 - 121 *
DATABASE GENBANK [online] VIGETTI D. ET AL: "Molecular cloning of mouse allantoicase cDNA", XP002991050, Database accession no. (AF278712) *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056138B2 (en) 2002-03-01 2015-06-16 Bracco Suisse Sa Multivalent constructs for therapeutic and diagnostic applications
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9381258B2 (en) 2002-03-01 2016-07-05 Bracco Suisse S.A. Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
WO2003000842A2 (en) 2003-01-03
JP2005518185A (en) 2005-06-23

Similar Documents

Publication Publication Date Title
WO2003000842A3 (en) Novel proteins and nucleic acids encoding same
WO2002081498A3 (en) Novel proteins and nucleic acids encoding same
WO2003010327A3 (en) Novel proteins and nucleic acids encoding same
WO2003040325A3 (en) Novel proteins and nucleic acids encoding same
WO2001036645A3 (en) Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same
WO2002072757A3 (en) Novel proteins and nucleic acids encoding same
WO2000053742A3 (en) Polynucleotides and proteins encoded thereby
WO2001049729A8 (en) Novex polypeptides, nucleic acids encoding same and their diagnostic and therapeutic use
WO2003083046A3 (en) Novel proteins and nucleic acids encoding same
WO2003023001A3 (en) Novel proteins and nucleic acids encoding same
WO2003029424A3 (en) Novel proteins and nucleic acids encoding same
WO2003064628A3 (en) Novel proteins and nucleic acids encoding same
WO2001074856A3 (en) Wnt-7b-like polypeptides and nucleic acids encoding same
WO2002002625A3 (en) Novel fibroblast growth factors and nucleic acids encoding same
WO2003102159A3 (en) Novel proteins and nucleic acids encoding same
WO2001062928A3 (en) Polypeptides and nucleic acids encoding same
WO2001070978A3 (en) Polypeptides and nucleic acids encoding same
WO2003025147A3 (en) Novel polynucleotides and proteins encoded thereby
WO2000061754A3 (en) Human proteins and polynucleotides encoding them
WO2001061009A3 (en) Polypeptides and nucleic acids encoding same
WO2001044473A3 (en) Polypeptides and nucleic acids encoding same
WO2004048512A3 (en) Novel proteins and nucleic acids encoding same
WO2001036638A8 (en) Polypeptides and nucleic acids encoding same
WO2003057854A3 (en) Novel proteins and nucleic acids encoding same
WO2003076642A3 (en) Novel proteins and nucleic acids encoding same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US US US US US US US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002329178

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2447941

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003507229

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002765778

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004104635

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002765778

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002765778

Country of ref document: EP